About the Authors
- Alessandra Vitelli
-
Affiliation Okairòs, Rome, Italy
- Mary R. Quirion
-
Affiliation Gene Therapy and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
- Chia-Yun Lo
-
Affiliation Gene Therapy and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
- Julia A. Misplon
-
Affiliation Gene Therapy and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
- Agnieszka K. Grabowska
-
Current address: German Cancer Research Center, Immunotherapy and Prevention, Heidelberg, Germany
Affiliation Okairòs, Rome, Italy
- Angiolo Pierantoni
-
Affiliation Okairòs, Rome, Italy
- Virginia Ammendola
-
Affiliation Okairòs, Rome, Italy
- Graeme E. Price
-
Affiliation Gene Therapy and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
- Mark R. Soboleski
-
Current address: Center for Devices and Radiological Health, Food and Drug Administration, White Oak, Maryland, United States of America
Affiliation Gene Therapy and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
- Riccardo Cortese
-
Affiliation Okairòs, Rome, Italy
- Stefano Colloca
-
Affiliation Okairòs, Rome, Italy
- Alfredo Nicosia
-
Affiliations Okairòs, Rome, Italy, Centro di Ingegneria Genetica e Biotecnologia Avanzate (CEINGE), Naples, Italy, Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples, Italy
- Suzanne L. Epstein
-
* E-mail: suzanne.epstein@fda.hhs.gov
Affiliation Gene Therapy and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
Competing Interests
The authors have the following interests: Authors from Okairòs are employees of and/or shareholders in Okairòs, which is developing vectored vaccines for malaria and other diseases. Okairòs is developing adenovirus based vaccines for influenza. This research was carried out under a collaborative agreement between CBER, FDA and Okairòs. There are no other patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: AN SLE AV MRQ C-YL JAM GEP. Performed the experiments: AV MRQ C-YL JAM GEP MRS AP AKG. Analyzed the data: AV MRQ C-YL JAM GEP MRS SLE AN. Contributed reagents/materials/analysis tools: AKG AP VA SC RC. Wrote the paper: SLE GEP AV MRQ C-YL JAM RC.